Archive · 25 Sep 2025
Sun Pharma: Brokerage Ratings and Investor Outlook
Two brokerages, Jefferies and Nuvama, have given different ratings for Sun Pharma.
Jefferies suggests buying the stock, predicting a 26% potential increase, due to expansion and new products, especially in India.
Nuvama recommends holding the stock, citing concerns about flat productivity and future challenges, with expectations of moderate growth and margin improvements.
The stock has seen a slight decline recently.
Jefferies recommends 'Buy' with a target price of Rs 2,070.
Jefferies anticipates growth from volume expansion and differentiated products.
Nuvama recommends 'Hold' with a target price of Rs 1,830.
Nuvama expects focus on domestic formulations and innovative medicines.
The stock is down 13% on a yearly basis.
- Who
- Sun Pharma and investors
- What
- Brokerage ratings and investor outlook on Sun Pharma shares
- When
- Recent
- Where
- India, US
- Why
- Brokerages have differing opinions on the company's future performance
Jefferies
Nuvama
Future Growth
Jefferies
Bullish: Expects growth driven by volume expansion and differentiated products.
Nuvama
Cautious: Expects moderate growth with concerns about productivity and future challenges.
- Jefferies Rating
- Buy
- Jefferies Target Price
- Rs 2,070
- Nuvama Rating
- Hold
- Nuvama Target Price
- Rs 1,830
- Sun Pharma Share Performance (Yearly)
- Down 13%